Skip to main content

Table 5 Estimated disease burden impacts of no vaccination, PCV13 2+1 and PHiD-CV 2+1 vaccination programs

From: Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

 

No vaccination

PCV13

PHiD-CV

PHiD-CV versus no vaccination

PHiD-CV versus PCV13

IPD cases (acute episodes)

2444

1295

1335

–1109

+40

 Meningitis

1021

533

550

–471

+17

 Bacteremia

1423

762

785

–638

+23

All-cause pneumonia cases (acute episodes)

534,819

510,143

510,140

–24,679

–3

AOM cases (acute episodes)

565,764

522,825

492,824

–72,940

–30,001

Pneumococcal deaths

239

132

136

–103

+4

 IPD

209

107

111

–98

+4

 Pneumonia

30

25

25

–5

0

  1. AOM acute otitis media, IPD invasive pneumococcal disease, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal polysaccharide and NTHi protein D conjugate vaccine
  2. In Malaysia over 10 years for a birth cohort of 508,774